Clinical Trial Update: CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating CP-547,632 in recurrent or persistent ovarian cancer, fallopian tube cancer, and primary peritoneal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• CP-547,632

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED